Your browser doesn't support javascript.
loading
(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort.
Bolhuis, Thomas E; Marsman, Diane; van den Hoogen, Frank H J; Broeder, Alfons A den; Broeder, Nathan den; van der Maas, Aatke.
Afiliación
  • Bolhuis TE; Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands. t.bolhuis@maartenskliniek.nl.
  • Marsman D; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. t.bolhuis@maartenskliniek.nl.
  • van den Hoogen FHJ; Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands.
  • Broeder AAD; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Broeder ND; Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands.
  • van der Maas A; Department of Rheumatology, Radboudumc, Nijmegen, The Netherlands.
BMC Rheumatol ; 6(1): 45, 2022 Aug 02.
Article en En | MEDLINE | ID: mdl-35915465
ABSTRACT

BACKGROUND:

To develop and assess a prediction model for polymyalgia rheumatica (PMR) relapse within the first year of glucocorticoid (GC) treatment.

METHODS:

A retrospective PMR cohort (clinical diagnosis) from a rheumatology department was used. All visits > 30 days after starting GC treatment and with > 2.5 mg/day oral prednisolone were used as potential relapse visits. Often used relapse criteria (1) rheumatologist judgement, (2) treatment intensification-based relapse) were assessed for agreement in this cohort. The proportion of patients with treatment-based relapse within 1 and 2 years of treatment and the relapse incidence rate were used to assess unadjusted associations with candidate predictors using logistic and Poisson regression respectively. After using a multiple imputation method, a multivariable model was developed and assessed to predict the occurrence (yes/no) of relapse within the first year of treatment.

RESULTS:

Data from 417 patients was used. Relapse occurred at 399 and 321 (of 2422) visits based on the rheumatologist judgement- and treatment-based criteria respectively, with low to moderate agreement between the two (87% (95% CI 0.86-0.88), with κ = 0.49 (95% CI 0.44-0.54)). Treatment-based relapse within the first two years was significantly associated with CRP, ESR, and pre-treatment symptom duration, and incidence rate with only CRP and ESR. A model to predict treatment intensification within the first year of treatment was developed using sex, medical history of cardiovascular disease and malignancies, pre-treatment symptom duration, ESR, and Hb, with an AUC of 0.60-0.65.

CONCLUSION:

PMR relapse occurs frequently, although commonly used criteria only show moderate agreement, underlining the importance of a uniform definition and criteria of a PMR specific relapse. A model to predict treatment intensification was developed using practical predictors, although its performance was modest.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: BMC Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: BMC Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos
...